June 7 (Reuters) - Cerus Corp:
* Cerus provides update on U.S. Platelet additive solution (pas) supply
* Cerus Corp - expected Fresenius Kabi pas shortage could be less disruptive to blood center production of intercept platelets than initially anticipated
* Cerus Corp - "cautiously optimistic that a future supply shortage for our customers has been mitigated by FDA decision"
* Cerus - expectation follows decision by FDA to review a recent submission by Fresenius Kabi as a changes being effected in 30 days (cbe-30) supplement Source text for Eikon: Further company coverage: